Enobosarm Clinical Trials (2026): 6 Studies for Metastatic Breast Cancer & Estrogen Receptor Negative
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
6 Enobosarm clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 5 indications (including Metastatic Breast Cancer & Estrogen Receptor Negative) and 452 total planned enrollment. 2 Phase 3 Enobosarm trials and 3 Phase 2 are listed. 1 Enobosarm clinical trial is actively recruiting at 10 U.S. sites across 6 states. Most recent activity: NCT07446998 (Dec 2027).
Where to Participate: All Enobosarm Trial Sites in the U.S. (10 sites across 6 states)
Every actively recruiting Enobosarmtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AZ | DM Clinical Research - Phoenix | Phoenix85012 | NCT07446998 | Map |
| FL | DM Clinical Research - MIA | Doral33166 | NCT07446998 | Map |
| FL | Universal Axon Clinical Research (Rovia - UACR) | Doral33166 | NCT07446998 | Map |
| FL | IMIC Research a Rovia Clinical Research Company | Miami33176 | NCT07446998 | Map |
| FL | Paramo Health | Miami33175 | NCT07446998 | Map |
| FL | Paramo Health | Miami33176 | NCT07446998 | Map |
| GA | UD Research | Atlanta30342 | NCT07446998 | Map |
| LA | Pennington Biomedical Research Center | Baton Rouge70808 | NCT07446998 | Map |
| MD | Centennial Medical Group (CMG) | Columbia21045 | NCT07446998 | Map |
| MS | SKY Integrative Medical Center | Ridgeland39157 | NCT07446998 | Map |
Enobosarm clinical trials at a glance: phase × recruitment status
| Phase | recruiting | completed | terminated | Total |
|---|---|---|---|---|
| P1 | 1 | 1 | ||
| P2 | 1 | 2 | 3 | |
| P3 | 2 | 2 |
Recruiting Enobosarm clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07446998 | PLATEAUProof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss | P2 | Obesity & Overweight | 200 | Mar 2026 |
Enobosarm clinical trials by indication
Metastatic Breast Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05065411 | VERU-024 | P3 | terminated | Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer |
| NCT04869943 | ARTEST | P3 | terminated | Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer |
Obesity & Overweight (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07446998 | PLATEAU | P2 | recruiting | Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss |
Muscle Loss (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06282458 | QUALITY | P2 | completed | Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt |
Androgen Receptor Positive (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02971761 | — | P2 | completed | Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer |
Mammographic Density (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03264651 | — | P1 | completed | Enobosarm and Anastrozole in Pre-menopausal Women With High Mammographic Breast Density |
Enobosarm pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| VERU-024 | NCT05065411 | P3 | terminated | Metastatic Breast Cancer | 5 | — |
| ARTEST | NCT04869943 | P3 | terminated | Metastatic Breast Cancer | 52 | — |
| PLATEAU | NCT07446998 | P2 | recruiting | Obesity & Overweight | 200 | — |
| QUALITY | NCT06282458 | P2 | completed | Muscle Loss | 168 | — |
Terminated and withdrawn Enobosarm trials (2)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT05065411terminatedEfficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer
- NCT04869943terminatedEfficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer
All Enobosarm trials (6)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07446998 | PLATEAU | Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss | P2 | recruiting | 200 | Veru Inc. | Mar 2026 |
| NCT06282458 | QUALITY | Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt | P2 | completed | 168 | Veru Inc. | Apr 2024 |
| NCT05065411 | VERU-024 | Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer | P3 | terminated | 5 | Veru Inc. | Apr 2022 |
| NCT04869943 | ARTEST | Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer | P3 | terminated | 52 | Veru Inc. | Oct 2021 |
| NCT02971761 | Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer | P2 | completed | 18 | City of Hope Medical Center | Jun 2017 | |
| NCT03264651 | Enobosarm and Anastrozole in Pre-menopausal Women With High Mammographic Breast Density | P1 | completed | 9 | Havah Therapeutics Pty Ltd | Feb 2017 |
Enobosarm clinical trials: frequently asked questions
- How many Enobosarm clinical trials are there?
- 6 Enobosarm clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants. 3 are marked completed.
- Are Enobosarm clinical trials recruiting in 2026?
- Yes — 1 Enobosarm trial is actively recruiting in 2026, with 10 U.S. sites across 6 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Enobosarm being studied for?
- Enobosarm is being studied for Metastatic Breast Cancer, Estrogen Receptor Negative, HER2/Neu Negative, HOMA-IR, Mammographic Density and 8 more. The trials are grouped by indication on this page.
- What phase is Enobosarm in?
- Enobosarm clinical trials span 2 Phase 3, 3 Phase 2, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Enobosarm clinical trials?
- The lead sponsor across the most Enobosarm trials is Veru Inc., with 2 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Enobosarmas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: